A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Akebia Therapeutics Inc’s current trading price is -8.71% away from its 52-week high, while its distance from the 52-week low is 365.10%. The stock’s price range for this time frame has been between $0.80 and $4.08. The trading volume of the company’s shares in the Healthcare reached around 2.7 million for the day, which was evidently lower than the average daily volume of 5.04 million over the last three months.
In terms of market performance, Akebia Therapeutics Inc had a somewhat regular. The highest value for the stock in the past year was $4.08 on 06/09/25, while the lowest value was $0.80 on 06/26/24.
How Financial Performance Impacts Market Capitalization
Akebia Therapeutics Inc (AKBA) has experienced a quarterly rise of 82.39% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 977.22M and boasts a workforce of 181 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
How AKBA’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for AKBA stands at 8.39. Similarly, the long-term debt-to-equity ratio is also 7.41.
AKBA Stock Price Performance Analysis
Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. The index has shown a price gain of 295.83% this year. Over the last six months, there has been a weaker performance of 111.41%. The price of AKBA fallen by 31.48% during the last 30 days period. For the last 5-days stocks have improved 3.93%.
